Pharmacological monitoring of azathioprine therapy.
作者： Reuther L. O. , Sonne J. , Larsen N. E. , Larsen B. , Christensen S.
DOI: 10.1080/00365520310005082
关键词:
摘要: Background: Studies on azathioprine (Aza) treatment in Crohn disease have indicated a positive correlation between clinical remission and concentration erythrocytes of the metabolites 6-thioguanine nucleotides (E-6-TGN) above 230 r pmol/8 × 10 8 RBC. A methylated Aza (E-6-MMP) 5000 RBC has been correlated to hepatotoxicity. Thiopurine methyltransferase (TPMT) is responsible for formation lower E-TGN levels, TPMT genotyping proposed as guidance dosage. In cross-sectional study we investigated relationships outcome dose, genotype metabolite levels among patients with disease. Methods: (PCR assay), (HPLC analysis) xanthine oxidase (XO) activity were determined once 71 randomly selected an unaltered dose at least 3 months. Results: Non...
core.ac.uk
informahealthcare.com参考文章(38)
Eugene Y. Krynetski, William E. Evans, Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Pharmaceutical Research. ,vol. 16, pp. 342- 349 ,(1999) , 10.1023/A:1011909315614
E. Y. Krynetski, N. F. Krynetskaia, T. Loennechen, M. Y. Fessing, Hung-Liang Tai, C. R. Yates, W. E. Evans, Thiopurine S-methyltransferase deficiency : Two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians American Journal of Human Genetics. ,vol. 58, pp. 694- 702 ,(1996)
C Cuffari, Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease Gut. ,vol. 48, pp. 642- 646 ,(2001) , 10.1136/GUT.48.5.642
L. Lennard, The clinical pharmacology of 6-mercaptopurine. European Journal of Clinical Pharmacology. ,vol. 43, pp. 329- 339 ,(1992) , 10.1007/BF02220605
William J Sandborn, William J Tremaine, Douglas C Wolf, Stephan R Targan, Charles A Sninsky, Lloyd R Sutherland, Stephen B Hanauer, John WD McDonald, Brian G Feagan, Richard N Fedorak, Kim L Isaacs, M Gennette Pike, Dennis C Mays, James J Lipsky, Susan Gordon, Christi S Kleoudis, Robert H Murdock Jr, North American Azathioprine Study Group, Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease Gastroenterology. ,vol. 117, pp. 527- 535 ,(1999) , 10.1016/S0016-5085(99)70445-2
Jos P.M. Bökkerink, Elisabet H. Stet, Ronney A. De Abreu, Frank J.M. Damen, Tilly W. Hulscher, Marinka A.H. Bakker, John A. Van Baal, 6-Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts. Biochemical Pharmacology. ,vol. 45, pp. 1455- 1463 ,(1993) , 10.1016/0006-2952(93)90045-X
W. J. Sandborn, Azathioprine: State of the Art in Inflammatory Bowel Disease Scandinavian Journal of Gastroenterology. ,vol. 225, pp. 92- 99 ,(1998) , 10.1080/003655298750027290
Jens Bo Thomsen, Henrik Schr�der, Jon Kristinsson, Bibi Madsen, Carol Szumlanski, Richard Weinshilboum, Jesper Brandt Andersen, Kjeld Schmiegelow, Possible Carcinogenic Effect of 6-mercaptopurine on Bone Marrow Stem Cells: Relation to Thiopurine Metabolism Cancer. ,vol. 86, pp. 1080- 1086 ,(1999) , 10.1002/(SICI)1097-0142(19990915)86:6<1080::AID-CNCR26>3.0.CO;2-5
Charles R Yates, Eugene Y Krynetski, Thrina Loennechen, Michael Y Fessing, Hung-Liang Tai, Ching-Hon Pui, Mary V Relling, William E Evans, Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance Annals of Internal Medicine. ,vol. 126, pp. 608- 614 ,(1997) , 10.7326/0003-4819-126-8-199704150-00003
RichardF. Harvey, M. Jane Bradshaw, MEASURING CROHN'S DISEASE ACTIVITY The Lancet. ,vol. 315, pp. 1134- 1135 ,(1980) , 10.1016/S0140-6736(80)91577-9